Pretomanid is a nitroimidazole antimicrobial active against drug-resistant Mycobacterium
tuberculosis and approved in combination with bedaquiline and linezolid (BPaL) to treat …

Tuberculosis (TB) is the most deadly infectious disease globally. Although most individuals
achieve a cure, a substantial portion develop multi-drug resistant TB which is exceedingly …

Shorter, more potent regimens are needed for tuberculosis. The nitroimidazole pretomanid
was recently approved for extensively drug-resistant tuberculosis in combination with …

Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB
antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data …

Pretomanid is a promising anti-tubercular drug currently at clinical phase III, but its
mechanisms of action are currently unclear. This study aimed to:(i) reveal the metabolome of …

Tuberculosis (TB) is the leading infectious cause of mortality worldwide. Despite the
development of different antituberculosis drugs, managing resistant mycobacteria is still …

There is often overlap in the diagnostic features of common pathologic processes such as
infection, sterile inflammation, and cancer both clinically and using conventional imaging …

Bedaquiline is a promising drug against tuberculosis (TB), but limited data are available on
its intralesional pharmacokinetics. Moreover, current techniques rely on invasive tissue …

Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the
BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid …

Background: Bacterial infections are still one of the main factors associated with mortality
worldwide. Many radiopharmaceuticals were developed for bacterial imaging, both with …